ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Mineralys Therapeutics, Inc. | MLYS | United States of America | $2.09B | 435 |
| Relay Therapeutics, Inc. | RLAY | United States of America | $2.95B | 609 |
| NEKTAR THERAPEUTICS | NKTR | United States of America | $2.32B | 1,913 |
| Tyra Biosciences, Inc. | TYRA | United States of America | $1.90B | 447 |
| Kodiak Sciences Inc. | KOD | United States of America | $1.94B | 441 |
| MESOBLAST LTD | MESO | United States of America | $1.78B | 2,142 |
| Viridian Therapeutics, Inc.\DE | VRDN | United States of America | $1.89B | 863 |
| Stoke Therapeutics, Inc. | STOK | United States of America | $1.87B | 659 |
| ANAPTYSBIO, INC | ANAB | United States of America | $1.97B | 746 |
| Pharvaris N.V. | PHVS | Netherlands | $2.44B | 361 |
| Enliven Therapeutics, Inc. | ELVN | United States of America | $1.84B | 800 |
| Sionna Therapeutics, Inc. | SION | United States of America | $1.99B | 250 |
| CAPRICOR THERAPEUTICS, INC. | CAPR | United States of America | $1.30B | 1,006 |
| Zymeworks Inc. | ZYME | United States of America | $1.96B | 423 |
| RAPT Therapeutics, Inc. | RAPT | United States of America | $1.68B | 572 |
| PALVELLA THERAPEUTICS, INC. | PVLA | United States of America | $1.67B | 832 |
| Amylyx Pharmaceuticals, Inc. | AMLX | United States of America | $1.48B | 490 |
| RECURSION PHARMACEUTICALS, INC. | RXRX | United States of America | $1.75B | 1,039 |
| Nurix Therapeutics, Inc. | NRIX | United States of America | $1.81B | 602 |
| uniQure N.V. | QURE | Netherlands | $2.84B | 973 |
| PELL Bio-Medical Co., Ltd. | 6949 | Taiwan | $1.44B | 502 |
| Oculis Holding AG | OCS | Switzerland | $1.83B | 461 |
| Trevi Therapeutics, Inc. | TRVI | United States of America | $2.49B | 573 |
| Intellia Therapeutics, Inc. | NTLA | United States of America | $1.51B | 776 |
| AtaiBeckley Inc. | ATAI | United States of America | $1.83B | 134 |
| Nanobiotix S.A. | NBTX | United States of America | $1.84B | 309 |
| Vir Biotechnology, Inc. | VIR | United States of America | $1.61B | 826 |
| Mind Medicine (MindMed) Inc. | MNMD | Canada | $1.46B | 503 |
| Nanobiotix | NANO | France | $2.09B | 928 |
| Biohaven Ltd. | BHVN | Virgin Islands (British) | $1.63B | 282 |
| Atai Beckley N.V. | ATAI | Netherlands | $2.67B | 318 |
| Monte Rosa Therapeutics, Inc. | GLUE | United States of America | $1.80B | 419 |
| MoonLake Immunotherapeutics | MLTX | United States of America | $1.70B | 345 |
| Rapport Therapeutics, Inc. | RAPP | United States of America | $1.32B | 255 |
| Wave Life Sciences Ltd. | WVE | United States of America | $1.10B | 818 |
| MBX Biosciences, Inc. | MBX | United States of America | $2.69B | 257 |
| Immatics N.V. | IMTX | Netherlands | $1.25B | 248 |
| Corvus Pharmaceuticals, Inc. | CRVS | United States of America | $935.09M | 641 |
| DBV Technologies | DBV | France | $984.17M | 1,832 |
| Olema Pharmaceuticals, Inc. | OLMA | United States of America | $1.10B | 578 |
| Taysha Gene Therapies, Inc. | TSHA | United States of America | $1.82B | 408 |
| Savara Inc | SVRA | United States of America | $1.24B | 1,300 |
| Oric Pharmaceuticals, Inc. | ORIC | United States of America | $788.80M | 463 |
| EyePoint, Inc. | EYPT | United States of America | $986.81M | 1,369 |
| Zenas BioPharma, Inc. | ZBIO | United States of America | $1.12B | 210 |
| ArriVent BioPharma, Inc. | AVBP | United States of America | $1.41B | 158 |
| Inventiva | IVA | France | $826.86M | 867 |
| AbCellera Biologics Inc. | ABCL | Canada | $1.07B | 401 |
| CureVac N.V. | CVAC | United States of America | $1.05B | 281 |
| Septerna, Inc. | SEPN | United States of America | $1.05B | 182 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.